Nathan Collins, Vice President, SRI Biosciences

Toggle Menu

Nathan Collins

Vice President, SRI Biosciences

Nathan Collins is responsible for research and development and leads the organization’s Centers for Cancer and Metabolism, Immunology and Infectious Diseases, and Chemical Biology located in Menlo Park, California and Harrisonburg, Virginia. The centers conduct basic and translational research in the life sciences. 

Specializing at the interface between innovative, translational R&D, and commercialization, Collins has more than 20 years of experience in the biotechnology industry and has worked for more than 10 years as an executive manager. His research experience covers drug discovery from basic research through to clinical development. He is also responsible for the development of SRI’s portfolio of drug discovery and diagnostics technologies.

In addition to drug research, Collins and his centers have established a number of new technology platforms at SRI, such as the Translational Neuroscience Program, which has led to a cognition research collaboration with Hoffman La Roche; a platform for the development of imaging biomarkers which led to a collaboration with Pentax; and the fiber‐optic array scanning technology (FAST) circulating tumor cell detection system, which can diagnose cancer through a simple blood test.

Prior to joining SRI, Collins was vice president of new product development for San Diego-based Discovery Partners International (DPI), where he established compound management as a business, winning the NIH Roadmap Small Molecule Repository and creating the new entity Compound Focus, which was ultimately acquired by the German drug discovery company Evotech. Prior to this, Collins was vice president of chemistry operations for DPI, where he helped build the high-throughput chemistry business. This led to a $100M+ collaboration with Pfizer, as well as several other multiple-year, multiple-million-dollar programs with companies such as Merck, Allergan, P&G, Aventis, and others. Collins started his industrial career at Arris Pharmaceuticals (later Axys Pharmaceuticals, and then Celera Genomics) in the discovery and development of small molecule drugs for protease inhibition, as well as small molecule cytokine mimetics.

Collins has a Ph.D. in chemistry and B.Sc. (Honors) in chemistry and mathematics from the University of Southampton in England. He was a postdoctoral research fellow at the University of Arizona’s Departments of Chemistry and Biochemistry.

Related News and Events

Hoffmann
SRI and F. Hoffmann-La Roche Launch Translational Medicine Collaboration to Study Methods and Treatments Associated with Cognitive Deficits across Neuropsychiatric Disorders - See more at: http://www-admin.sri.com/newsroom/press-releases/sri-international-and-f...
SRI and F. Hoffmann-La Roche Launch Translational Medicine Collaboration to Study Methods and Treatments Associated with Cognitive Deficits across Neuropsychiatric Disorders - See more at: http://www-admin.sri.com/newsroom/press-releases/sri-international-and-f...
SRI and F. Hoffmann-La Roche Launch Translational Medicine Collaboration to Study Methods and Treatments Associated with Cognitive Deficits across Neuropsychiatric Disorders - See more at: http://www-admin.sri.com/newsroom/press-releases/sri-international-and-f...
SRI and F. Hoffmann-La Roche Launch Translational Medicine Collaboration to Study Methods and Treatments Associated with Cognitive Deficits across Neuropsychiatric Disorders - See more at: http://www-admin.sri.com/newsroom/press-releases/sri-international-and-f...
Nathan Collins